Onco Actu du 6 avril 2020

	3.8 PRÉVENTION - ALIMENTATION
High-Fiber Foods Linked to Lower Breast Cancer Risk [NY Times] The analysis, in the journal Cancer, pooled data from 20 prospective studies of fiber consumption and breast cancer incidence.
	5. TRAITEMENTS
Cancer Researchers Use Evolution to Target Drug Resistance [The Scientist] New therapeutic approaches in oncology aim to manipulate or block cancer’s adaptation to treatment.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
J&J inks Fate deal to move into allogeneic CAR therapies [Fierce Biotech] In iPSCs, Fate has access to a source of cells that could fit the bill, leading it to advance a pipeline of off-the-shelf therapies spearheaded by clinical-phase NK candidate FT500 and enter into a collaboration with Ono Pharmaceutical.
Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies [Xconomy] The San Diego-based biotech has built a pipeline of experimental cell therapies that use induced pluripotent stem cells (iPSCs) to create chimeric antigen receptor (CAR) T-cell and CAR natural killer (NK) cell treatments.
Fate inks $100M J&J pact for 'off-the-shelf' cancer cell therapies [Biopharma Dive] The pact is the latest bet by a large drugmaker on allogeneic cell therapies, which could be cheaper to make and more convenient than the "autologous" CAR-T treatments that have won approval but struggled commercially.
	5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
Servier snaps up antibody biotech Symphogen, looks to become 'recognized oncology player' [Fierce Biotech] The deal, financial terms of which have not been made public, unusually, moves Servier’s R&D more deeply into oncology, building on its recent pact with Cellectis and its cell therapies.
Servier bags an antibody specialist in its latest oncology M&A deal with plans to add the platform tech [EndPoints] They’ve been working with Symphogen on a slate of programs, including some favs – PD-1, LAG3 and TIM3 — where they are looking to differentiate themselves from the more prominent drugs in these niches.
	5.2.6 PHARMA - BIOTECH
Zentalis pulls off speedy $165M IPO amid pandemic-driven uncertainty [Fierce Biotech] The company teamed up with Pfizer in May 2018 to test it alongside Pfizer’s CDK4/6 inhibitor Ibrance and expects to report data from a phase 1/2 study of the combo, as well as ZN-c5 as a single agent, later this year.
Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials [Xconomy] Zentalis’s lead drug candidate, ZN-c5, is a potential treatment for breast cancer. The drug is intended as a treatment for cancers that are estrogen receptor positive. The Zentalis pill is what’s called a selective estrogren receptor degrader (SERD).
Immunomedics Announces ASCENT Study to be Stopped for Compelling Efficacy [Immunomedics] This decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC), during its recent routine review of the ASCENT study. ASCENT is a Phase 3 confirmatory study designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a Phase 2 study of heavily pretreated patients with metastatic TNBC (mTNBC).
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Protecting Patients with Cancer Against Severe COVID-19 Disease in France [ESMO] Guidelines commissioned by the French health authorities.
Cancer guidelines during the COVID-19 pandemic [The Lancet Oncology] Oncology societies and national authorities have been quick to issue guidelines on cancer care during the pandemic.